Poster
80
(#80) Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia
Psych Congress 2025
Abstract: INTRODUCTION: Weight gain associated with antipsychotic treatment may contribute to nonadherence and subsequent increased risk of hospitalization. Combined olanzapine/samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain in patients with schizophrenia. This analysis compared treatment patterns and acute care events in patients with schizophrenia initiating OLZ/SAM versus olanzapine.
METHODS: This claims analysis used Komodo Healthcare Map data (10/18/2020-12/31/2023). Adults with schizophrenia enrolled in Medicaid with ≥1 OLZ/SAM or olanzapine claim were eligible. Patients were propensity score matched 1:1 on demographic/clinical variables. Treatment patterns (adherence, persistence, discontinuation), inpatient (IP) admissions, emergency department (ED) visits, numbers of days hospitalized per patient, and times to first IP admission were compared in a 12-month follow-up period.
RESULTS: After matching, 1614 patients with schizophrenia (OLZ/SAM, n=807; olanzapine, n=807) were included. OLZ/SAM was associated with significantly (P 0.001) higher adherence, longer persistence, and lower discontinuation rates over 12 months versus olanzapine. OLZ/SAM was associated with significantly (P 0.001) lower likelihood of ≥1 all-cause, mental health-related, or schizophrenia-related IP admission (odds ratio [OR] range, 0.52-0.59) or ED visit (OR range, 0.47-0.54). Across all-cause, mental health-related, and schizophrenia-related events, mean times to first IP admission were significantly (P 0.01) longer (range, 29-38 days) and mean numbers of days hospitalized per patient were significantly (P 0.01) lower (range, -4.7 to -5.7 days) in patients with schizophrenia initiating OLZ/SAM versus olanzapine.
CONCLUSIONS: OLZ/SAM treatment offers meaningful real-world effectiveness benefits over olanzapine alone, as observed by favorable treatment patterns and lower likelihood of relapse and related acute care events.
Short Description: This real-world claims analysis compared combined olanzapine/samidorphan (OLZ/SAM) versus olanzapine in patients with schizophrenia. OLZ/SAM was associated with significantly better adherence, longer persistence, and lower discontinuation rates. Patients initiating OLZ/SAM had lower odds of inpatient admissions and emergency department visits, longer time to first hospitalization, and fewer days hospitalized versus those initiating olanzapine. These findings highlight OLZ/SAM's real-world effectiveness and potential to reduce relapse and acute care burden compared with olanzapine alone.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
METHODS: This claims analysis used Komodo Healthcare Map data (10/18/2020-12/31/2023). Adults with schizophrenia enrolled in Medicaid with ≥1 OLZ/SAM or olanzapine claim were eligible. Patients were propensity score matched 1:1 on demographic/clinical variables. Treatment patterns (adherence, persistence, discontinuation), inpatient (IP) admissions, emergency department (ED) visits, numbers of days hospitalized per patient, and times to first IP admission were compared in a 12-month follow-up period.
RESULTS: After matching, 1614 patients with schizophrenia (OLZ/SAM, n=807; olanzapine, n=807) were included. OLZ/SAM was associated with significantly (P 0.001) higher adherence, longer persistence, and lower discontinuation rates over 12 months versus olanzapine. OLZ/SAM was associated with significantly (P 0.001) lower likelihood of ≥1 all-cause, mental health-related, or schizophrenia-related IP admission (odds ratio [OR] range, 0.52-0.59) or ED visit (OR range, 0.47-0.54). Across all-cause, mental health-related, and schizophrenia-related events, mean times to first IP admission were significantly (P 0.01) longer (range, 29-38 days) and mean numbers of days hospitalized per patient were significantly (P 0.01) lower (range, -4.7 to -5.7 days) in patients with schizophrenia initiating OLZ/SAM versus olanzapine.
CONCLUSIONS: OLZ/SAM treatment offers meaningful real-world effectiveness benefits over olanzapine alone, as observed by favorable treatment patterns and lower likelihood of relapse and related acute care events.
Short Description: This real-world claims analysis compared combined olanzapine/samidorphan (OLZ/SAM) versus olanzapine in patients with schizophrenia. OLZ/SAM was associated with significantly better adherence, longer persistence, and lower discontinuation rates. Patients initiating OLZ/SAM had lower odds of inpatient admissions and emergency department visits, longer time to first hospitalization, and fewer days hospitalized versus those initiating olanzapine. These findings highlight OLZ/SAM's real-world effectiveness and potential to reduce relapse and acute care burden compared with olanzapine alone.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
